Sera Prognostics

Category Archives

Sera Prognostics Announces Early Limited Commercial Access of Its PreTRM™ Test

SALT LAKE CITY, (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced a program for early limited commercial access Read more...

Immunoassay Confirmation of MRM-MS Data Supports a Role for Acute Phase Proteins in the Prediction of Spontaneous Preterm Birth

Sera Prognostics, Inc. presented data demonstrating correlation between ELISA and MRM-MS at the Society of Reproductive Investigation 2015 Annual Meeting.  Read more...

Bill & Melinda Gates Foundation Has Agreed to Join Series B Financing

Sera Prognostics, Inc., a women’s healthcare company, today announced that the Bill & Melinda Gates Foundation has agreed to join the Company’s Read more...

Sera Prognostics Closes $20 Million in Series B Financing

Sera Prognostics, Inc., a women’s healthcare company, today announced that it has closed $20 Million in Series B financing.  Leading the Series B investment Read more...

Sera Prognostics to Present at 33rd Annual J.P. Morgan Healthcare Conference

Sera Prognostics, Inc., a women’s healthcare company, today announced that Gregory C. Critchfield, M.D., M.S., Chairman and Chief Executive Officer, Read more...

Discovery Assay Development of Biomarkers Predictive of Preterm Birth

Sera Prognostics, Inc. presented the development and analytical performance of a highly multiplexed and targeted mass spectrometry-based assay for biomarker Read more...

Sera Prognostics to Present Data on the Discovery of Serum Biomarkers Predictive of Preterm Birth

Jay Boniface, Ph.D., Chief Scientific Officer of Sera Prognostics, will present data on the discovery of novel proteomic biomarkers associated with multiple Read more...

Dr. Leroy Hood Joins Sera Prognostics as a Scientific Advisor

SALT LAKE CITY, Utah (September 4, 2013) – Sera Prognostics, Inc., a women’s healthcare company, today announced that Lee Hood, M.D., Ph.D., noted Read more...

Sera Prognostics Completes Enrollment of PAPR Clinical Study

SALT LAKE CITY, Utah (August 21, 2013) – Sera Prognostics, Inc., a women’s healthcare company, today announced that it has completed enrollment of Read more...

Enrollment Exceeds 4,000 in Sera Prognostics’ Preterm Birth Clinical Study

Large Clinical Cohorts for Preterm Birth Prediction Form the Basis of Sera’s Rigorous Diagnostic Development SALT LAKE CITY, Utah (February 28, 2013) Read more...

Page 2 of 3123

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184